31 related articles for article (PubMed ID: 35749909)
1. Predictive value of CDC37 gene expression for targeted therapy in metastatic colorectal cancer.
Arai H; Yang Y; Baca Y; Millstein J; Denda T; Ou FS; Innocenti F; Takeda H; Kubota Y; Doi A; Horie Y; Umemoto K; Izawa N; Wang J; Battaglin F; Jayachandran P; Algaze S; Soni S; Zhang W; Goldberg RM; Hall MJ; Scott AJ; Hwang JJ; Lou E; Weinberg BA; Marshall J; Goel S; Xiu J; Michael Korn W; Venook AP; Sunakawa Y; Lenz HJ
Eur J Cancer; 2024 Apr; 201():113914. PubMed ID: 38359495
[TBL] [Abstract][Full Text] [Related]
2. The Oncology Biomarker Discovery framework reveals cetuximab and bevacizumab response patterns in metastatic colorectal cancer.
Ohnmacht AJ; Stahler A; Stintzing S; Modest DP; Holch JW; Westphalen CB; Hölzel L; Schübel MK; Galhoz A; Farnoud A; Ud-Dean M; Vehling-Kaiser U; Decker T; Moehler M; Heinig M; Heinemann V; Menden MP
Nat Commun; 2023 Sep; 14(1):5391. PubMed ID: 37666855
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness of bevacizumab in the treatment of metastatic colorectal cancer: a systematic review and meta-analysis.
Song Y; Mao Q; Zhou M; Liu CJ; Kong L; Hu T
BMC Gastroenterol; 2024 Feb; 24(1):58. PubMed ID: 38302922
[TBL] [Abstract][Full Text] [Related]
4. Tumor Immunogenomic Features Determine Outcomes in Patients with Metastatic Colorectal Cancer Treated with Standard-of-Care Combinations of Bevacizumab and Cetuximab.
Innocenti F; Yazdani A; Rashid N; Qu X; Ou FS; Van Buren S; Bertagnolli MM; Kabbarah O; Blanke CD; Venook AP; Lenz HJ; Vincent BG
Clin Cancer Res; 2022 Apr; 28(8):1690-1700. PubMed ID: 35176136
[TBL] [Abstract][Full Text] [Related]
5. Integration of bulk RNA sequencing data and single-cell RNA sequencing analysis on the heterogeneity in patients with colorectal cancer.
Zhang J; Wu Y; Shen Z
Funct Integr Genomics; 2023 Jun; 23(3):209. PubMed ID: 37355491
[TBL] [Abstract][Full Text] [Related]
6. Down-regulation of stimulator of interferon genes (STING) expression and CD8
Fukai S; Nakajima S; Saito M; Saito K; Kase K; Nakano H; Sato T; Sakuma M; Kaneta A; Okayama H; Mimura K; Sakamoto W; Saze Z; Momma T; Kono K
Gastric Cancer; 2023 Nov; 26(6):878-890. PubMed ID: 37542528
[TBL] [Abstract][Full Text] [Related]
7. Comparative Effectiveness of Bevacizumab versus Cetuximab in Metastatic Colorectal Cancer Patients without Primary Tumor Resection.
Su YC; Wu CC; Su CC; Hsieh MC; Cheng CL; Kao Yang YH
Cancers (Basel); 2022 Apr; 14(9):. PubMed ID: 35565247
[TBL] [Abstract][Full Text] [Related]
8. Prognostic significance of STING expression in solid tumor: a systematic review and meta-analysis.
Kim Y; Cho NY; Jin L; Jin HY; Kang GH
Front Oncol; 2023; 13():1244962. PubMed ID: 37711192
[TBL] [Abstract][Full Text] [Related]
9. Correction: The effectiveness and safety of bevacizumab versus cetuximab in the treatment of colorectal cancer: a systematic review and meta‑analysis.
Cui Y; Guo Y
Int J Clin Pharm; 2024 Apr; 46(2):555-557. PubMed ID: 38270779
[No Abstract] [Full Text] [Related]
10. Impact of genetic variants involved in the lipid metabolism pathway on progression free survival in patients receiving bevacizumab-based chemotherapy in metastatic colorectal cancer: a retrospective analysis of FIRE-3 and MAVERICC trials.
Wang J; Millstein J; Yang Y; Stintzing S; Arai H; Battaglin F; Kawanishi N; Soni S; Zhang W; Mancao C; Cremolini C; Liu T; Heinemann V; Falcone A; Shen L; Lenz HJ
EClinicalMedicine; 2023 Mar; 57():101827. PubMed ID: 36816347
[TBL] [Abstract][Full Text] [Related]
11. Mutational analysis of microsatellite-stable gastrointestinal cancer with high tumour mutational burden: a retrospective cohort study.
Wang J; Xiu J; Farrell A; Baca Y; Arai H; Battaglin F; Kawanishi N; Soni S; Zhang W; Millstein J; Shields AF; Grothey A; Weinberg BA; Marshall JL; Lou E; Khushman M; Sohal DPS; Hall MJ; Liu T; Oberley M; Spetzler D; Korn WM; Shen L; Lenz HJ
Lancet Oncol; 2023 Feb; 24(2):151-161. PubMed ID: 36681091
[TBL] [Abstract][Full Text] [Related]
12. Current Targeted Therapy for Metastatic Colorectal Cancer.
Ohishi T; Kaneko MK; Yoshida Y; Takashima A; Kato Y; Kawada M
Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36675216
[TBL] [Abstract][Full Text] [Related]
13. Pharmacogenetics Role of Genetic Variants in Immune-Related Factors: A Systematic Review Focusing on mCRC.
Scarabel L; Bignucolo A; Toffoli G; Cecchin E; De Mattia E
Pharmaceutics; 2022 Nov; 14(11):. PubMed ID: 36432658
[TBL] [Abstract][Full Text] [Related]
14. cGAS-STING pathway targeted therapies and their applications in the treatment of high-grade glioma.
Tripathi S; Najem H; Mahajan AS; Zhang P; Low JT; Stegh AH; Curran MA; Ashley DM; James CD; Heimberger AB
F1000Res; 2022; 11():1010. PubMed ID: 36324813
[TBL] [Abstract][Full Text] [Related]
15. Genetic variants involved in the cGAS-STING pathway predict outcome in patients with metastatic colorectal cancer: Data from FIRE-3 and TRIBE trials.
Wang J; Xiao Y; Loupakis F; Stintzing S; Yang Y; Arai H; Battaglin F; Kawanishi N; Jayachandran P; Soni S; Zhang W; Mancao C; Cremolini C; Liu T; Heinemann V; Falcone A; Shen L; Millstein J; Lenz HJ
Eur J Cancer; 2022 Sep; 172():22-30. PubMed ID: 35749909
[TBL] [Abstract][Full Text] [Related]
16. Germ line polymorphisms of genes involved in pluripotency transcription factors predict efficacy of cetuximab in metastatic colorectal cancer.
Arai H; Millstein J; Loupakis F; Stintzing S; Wang J; Battaglin F; Kawanishi N; Jayachandran P; Soni S; Zhang W; Mumenthaler SM; Cremolini C; Heinemann V; Falcone A; Lenz HJ
Eur J Cancer; 2021 Jun; 150():133-142. PubMed ID: 33901792
[TBL] [Abstract][Full Text] [Related]
17. Germline Polymorphisms in Genes Involved in the Antioxidant System Predict the Efficacy of Cetuximab in Metastatic Colorectal Cancer Patients Enrolled in FIRE-3 Trial.
Arai H; Millstein J; Yang Y; Stintzing S; Wang J; Battaglin F; Kawanishi N; Jayachandran P; Soni S; Zhang W; Heinemann V; Lenz HJ
Clin Colorectal Cancer; 2022 Sep; 21(3):259-266. PubMed ID: 35710481
[TBL] [Abstract][Full Text] [Related]
18. Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial.
Venook AP; Niedzwiecki D; Lenz HJ; Innocenti F; Fruth B; Meyerhardt JA; Schrag D; Greene C; O'Neil BH; Atkins JN; Berry S; Polite BN; O'Reilly EM; Goldberg RM; Hochster HS; Schilsky RL; Bertagnolli MM; El-Khoueiry AB; Watson P; Benson AB; Mulkerin DL; Mayer RJ; Blanke C
JAMA; 2017 Jun; 317(23):2392-2401. PubMed ID: 28632865
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
